NASDAQ:AIMT

Aimmune Therapeutics (AIMT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$34.49
$34.49
50-Day Range
$34.30
$34.59
52-Week Range
$10.09
$37.00
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AIMT stock logo

About Aimmune Therapeutics Stock (NASDAQ:AIMT)

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

AIMT Stock News Headlines

See More Headlines
Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/30/2020
Today
5/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AIMT
Fax
N/A
Employees
228
Year Founded
N/A

Profitability

Net Income
$-248,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.66 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.76
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Jayson Donald Alexander Dallas (Age 51)
    Pres, CEO & Director
  • Mr. Eric H. Bjerkholt (Age 59)
    Chief Financial Officer
  • Mr. Douglas T. Sheehy (Age 52)
    Gen. Counsel & Sec.
  • Dr. Stephen George Dilly (Age 59)
    Special Advisor
  • Dr. Daniel C. Adelman (Age 62)
    Chief Medical Officer

AIMT Stock Analysis - Frequently Asked Questions

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced its earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, meeting analysts' consensus estimates of ($1.06).

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Block (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU).

When did Aimmune Therapeutics IPO?

Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

This page (NASDAQ:AIMT) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners